RxDoctor Payments Data

Hanson Lee, MD

Gastroenterology · Arcadia, CANPI 1730181116

Payments from drug & device makers

$2,488in general payments, 2019–2025

Across 100 payments — averaging $24.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$579
  • Johnson & Johnson$352
  • Ironwood Pharmaceuticals, Inc$298
  • Amgen$242
  • Madrigal Pharmaceuticals$191
  • Ardelyx, Inc.$177
  • plus $650 from 17 others

What the payments were for

  • Food & beverage$2,38696%
  • Education$1024%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,488 in reported general payments places this provider in the 50th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$198,031
Medicare patients
566
Services billed
1,722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase52$130,597
ZenpepLipase/Protease/Amylase26$65,649
LinzessLinaclotide37$23,435
VemlidyTenofovir Alafenamide14$22,553
Famotidine724$8,274
Lactulose182$5,872
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl272$4,568
Mesalamine16$4,487
Omeprazole308$2,750
Entecavir29$2,602
Tenofovir Disoproxil Fumarate12$2,071
Ursodiol18$1,513
Sucralfate32$878
Pantoprazole Sodium54$673
EnuloseLactulose11$612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$579$154,03289 claims
Aimmune Therapeutics, Inc.Zenpep$54$65,64926 claims
GileadVemlidy$27$22,55314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →